Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.42 |
| ▸ | MITF | O75030 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.42 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 5/20 | 0.38 |
| ▸ | TP53 | P04637 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9860360 | 0.93 | MEN1 (0.54) | MEN1KMT2ASMN1; SMN2MITFALDH1A1 | |
| SCHEMBL9860590 | 0.90 | SMN1; SMN2 (0.52) | MEN1KMT2ASMN1; SMN2MITFALDH1A1 | |
| SCHEMBL9860310 | 0.85 | MEN1 (0.53) | MEN1KMT2ASMN1; SMN2MITFALDH1A1 | |
| SCHEMBL5726231 | 0.84 | KMT2A (0.53) | MEN1KMT2ASMN1; SMN2MITFALDH1A1 | |
| SCHEMBL5725306 | 0.84 | KMT2A (0.52) | MEN1KMT2ASMN1; SMN2MITFALDH1A1 | |
| SCHEMBL5725870 | 0.80 | TBXAS1 (0.49) | MEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL22504269 | 0.80 | KMT2A (0.52) | MEN1KMT2ASLC6A3KDM4CTDP1 | |
| SCHEMBL5726245 | 0.79 | KMT2A (0.49) | MEN1KMT2ASMN1; SMN2MITFALDH1A1 | |
| SCHEMBL9860316 | 0.78 | MEN1 (0.46) | MEN1KMT2ASMN1; SMN2RAB9AKDM4C | |
| SCHEMBL21886902 | 0.78 | SLC6A3 (0.53) | MEN1KMT2AALDH1A1SLC6A3KDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10138190-B2 | Process for preparation of ospemifene | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2018-11-27 | — | — | US | disclosed |
| US-20180022674-A1 | PROCESS FOR PREPARATION OF OSPEMIFENE | GLENMARK LIFE SCIENCES LIMITED (IN) | 2018-01-25 | — | — | US | disclosed |
| US-20180022674-A1 | PROCESS FOR PREPARATION OF OSPEMIFENE | GLENMARK LIFE SCIENCES LIMITED (IN) | 2018-01-25 | — | — | US | disclosed |
| US-20180022674-A1 | PROCESS FOR PREPARATION OF OSPEMIFENE | GLENMARK LIFE SCIENCES LIMITED (IN) | 2018-01-25 | — | — | US | disclosed |
| WO-2016110805-A1 | PROCESS FOR PREPARATION OF OSPEMIFENE | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2016-07-14 | — | — | WO | disclosed |
| WO-2016110805-A1 | PROCESS FOR PREPARATION OF OSPEMIFENE | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2016-07-14 | — | — | WO | disclosed |
| EP-1705169-A2 | Triphenylalkene derivatives and their use as selective estrogen receptor modulators | Hormos Medical Ltd. (FI) | 2006-09-27 | — | — | EP | disclosed |
| EP-1235776-B1 | TRIPHENYLALKENE DERIVATIVES AND THEIR USE AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | HORMOS MEDICAL CORP (FI) | 2006-02-08 | — | — | EP | disclosed |
| US-6875775-B2 | Triphenylalkene derivatives and their use as selective estrogen receptor modulators | HORMOS MEDICAL OY LTD (FI) | 2005-04-05 | — | — | US | disclosed |
| US-20030225130-A1 | Triphenylalkene derivatives and their use as selective estrogen receptor modulators | HORMOS MEDICAL OY LTD. | 2003-12-04 | — | — | US | disclosed |
| US-6576645-B1 | Such as 3-(4-chloro-1-(4-(2-(2-hydroxyethoxy)ethoxy)phenyl)--2-phenylbut-1 -enyl)phenol; producing tissue specific estro-genic and/or antiestrogenic effect | HORMOS MEDICAL OY LTD (FI) | 2003-06-10 | — | — | US | disclosed |
| US-4996225-A | Antitumor agents | FARMOS GROUP LTD. (FI) | 1991-02-26 | — | — | US | disclosed |
| US-4696949-A | ANTITUMOR AGENTS, ANTIESTROGENS | FARMOS GROUP LTD. (FI) | 1987-09-29 | — | — | US | disclosed |
| EP-0095875-B1 | NOVEL TRI-PHENYL ALKANE AND ALKENE DERIVATIVES AND THEIR PREPARATION AND USE | Farmos Group Ltd. (FI) | 1986-09-10 | — | — | EP | disclosed |
| EP-0095875-A2 | Novel tri-phenyl alkane and alkene derivatives and their preparation and use | Farmos Group Ltd. (FI) | 1983-12-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10138190-B2 | Process for preparation of ospemifene | CYP3A4, MME, CYP4B1 | MEN1 3770/4885KMT2A 1183/4885SMN1; SMN2 883/4885 |
| US-20030225130-A1 | Triphenylalkene derivatives and their use as selective estrogen receptor modulators | ESR2, ESR1, GPER1 | MEN1 3414/4885KMT2A 987/4885SMN1; SMN2 4365/4885 |
| US-20180022674-A1 | PROCESS FOR PREPARATION OF OSPEMIFENE | CYP3A4, MME, CYP4B1 | MEN1 3770/4885KMT2A 1183/4885SMN1; SMN2 883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.